Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3

Abstract

// Shicong Zhu 1, * , Zhihua Wang 1, * , Zijian Li 1, 2 , Hongling Peng 1 , Yunya Luo 1 , Mingyang Deng 1 , Ruijuan Li 1 , Chongwen Dai 1 , Yunxiao Xu 1 , Sufang Liu 1 , Guangsen Zhang 1 1 Division of Hematology, Institute of Molecular Hematology, The Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China 2 Division of Hematology, The First Affiliated Hospital, Lanzhou University, Lanzhou, Gansu, China * These authors have contributed equally to this work Corresponding to: Guangsen Zhang, e-mail: zgsllzy@163.com Keywords: icaritin, multiple myeloma, antitumor activities, IL6/JAK2/STAT3 signaling Received: January 19, 2015      Accepted: February 15, 2015      Published: March 16, 2015 ABSTRACT Icaritin is an active prenylflavonoid derived from Epimedium genus, a traditional Chinese medicine. Icaritin has a wide range of pharmacological and biological activities, including cardiovascular function improvement, hormone regulation and antitumor activity. Here, we investigated the effect of icaritin on multiple myeloma (MM) in vitro and in vivo . Icaritin inhibited cell growth of MM cell line and primary MM cells. In contrast, icaritin had low or no cytotoxic effect on normal hematopoiesis. We also demonstrated that in MM xenograft mouse models, icaritin suppressed tumor growth and decreased serum IL-6 and IgE levels, but did not show adverse reactions such as body weight loss. The anti-MM activity of icaritin was mainly mediated by inhibiting IL-6/JAK2/STAT3 signaling. We suggest that icaritin can be further tested in clinical trials in MM.